1/42
Looks like no tags are added yet.
Inborn errors of metabolism
Genetic disorders caused by enzyme deficiencies in metabolic pathways.
Garrod’s hypothesis
Metabolic disease results from substrate buildup, product deficiency, and toxic intermediates.
Most metabolic disorders inheritance pattern
Autosomal recessive.
Phenylalanine hydroxylase (PAH)
Enzyme converting phenylalanine to tyrosine; deficient in PKU.
Cofactor required for PAH
Tetrahydrobiopterin (BH4).
Biochemical abnormality in PKU
High phenylalanine, low tyrosine, phenylketones in urine.
Phenylpyruvate
Toxic phenylalanine metabolite elevated in PKU.
Phenylacetate
PKU metabolite responsible for musty odor.
Phenyllactate
Alternate phenylalanine metabolite elevated in PKU.
Normal plasma phenylalanine
Classic PKU phenylalanine levels
20× normal.
Mild PKU phenylalanine levels
10–15× normal.
Non-PKU hyperphenylalaninemia
2–8× normal; often asymptomatic.
Age dependency of Phe toxicity
High Phe more harmful in young children due to brain development.
Major pathogenic mechanism of PKU
Phe outcompetes Tyr/Trp at LAT1 transporter → low neurotransmitters.
Neurotransmitters affected in PKU
Dopamine, norepinephrine, serotonin.
Why hypopigmentation occurs in PKU
Low tyrosine → low melanin synthesis.
Why tyrosine supplementation alone fails
Transporter competition prevents Tyr from entering brain.
Alternate phenylalanine pathways in PKU
Phenylalanine → phenylpyruvate → phenyllactate/phenylacetate.
Clinical symptoms of PKU
Intellectual disability, seizures, tremors, behavioral issues, hypopigmentation.
Newborn screening test for PKU
Guthrie bacterial inhibition assay.
Criteria for newborn screening
Cheap, stable metabolite, small blood volume, treatable disease.
Aspartame relevance to PKU
Contains phenylalanine; must be avoided.
BH4 therapy (Kuvan)
Effective only in mild PKU with residual PAH activity.
PAL enzyme therapy
Phenylalanine ammonia lyase converts Phe → trans-cinnamate.
Pegvaliase (Palynziq)
Pegylated PAL enzyme; reduces immunogenicity; lowers Phe.
Engineered microbiome therapy (SYNB1618)
E. coli Nissle engineered to degrade phenylalanine → hippurate.
Urea cycle disorders
Cause hyperammonemia; elevated arginine/citrulline.
Amino acids elevated in MSUD
Leucine, isoleucine, valine.
Odor of PKU
Musty or mousy.
Odor of MSUD
Maple syrup.
Odor of trimethylaminuria
Rotten fish.
Central role of glutamate in nitrogen metabolism
Primary amino group donor for transamination.
Central role of aspartate in nitrogen metabolism
Provides nitrogen for urea cycle.
Aromatic amino acid hydroxylases
Require BH4 cofactor.
Aromatic amino acid decarboxylase
Requires PLP (vitamin B6).
Phenylalanine transport issue in PKU
Phe saturates LAT1 transporter at BBB → blocks Tyr/Trp entry.
Defective brain myelination in PKU
Chronic and irreversible due to low protein synthesis.
Dietary treatment for PKU
Strict lifelong low-Phe diet + Phe-free amino acid formula.
Synthetic Phe-free formula issues
Bad taste, nutrient deficiencies, emotional stress, high cost.
Why PKU must be treated early
Prevent irreversible cognitive impairment.
PAH mutation types
Null, Vmax reduction, kinetic defects, unstable protein.
Genotype–phenotype correlation in PKU
Strong at enzyme level; weaker at cognitive level due to modifiers.